We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Large-Scale Schizophrenia Exome Sequencing Identifies New Risk Genes

By LabMedica International staff writers
Posted on 31 Oct 2019
Schizophrenia affects about 0.7% of the population and shortens life expectancy by 12 to 15 years. More...
Though it has long been known to have a genetic component, little progress has been made in identifying new targets for therapy.

Schizophrenia is a mental illness characterized by abnormal behavior, strange speech, and a decreased ability to understand reality. Other symptoms may include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression, and lack of motivation.

Molecular Geneticists at the Broad Institute (Cambridge, MA, USA) and their associates have identified new genes involved in schizophrenia by analyzing the exomes of almost 25,000 schizophrenia cases and 100,000 unaffected controls. The team decided to look at ultra-rare coding variants, which occur with much lower frequency but also have a greater effect size. In order to have sufficient power to find these types of variants, they needed to look at the exomes of a very large number of cases and controls. While genome-wide association studies (GWAS) have already identified hundreds of risk loci for schizophrenia, it has been difficult to go from these associations to causal variants, specific genes involved, and the function of these genes.

The scientists recruited schizophrenia patients and controls from several populations, including those with European, Latin American, East Asian, Ashkenazi Jewish, and African American ancestry, though the majority have a European background. So far, they have analyzed the exomes of 24,248 cases and 97,322 controls, and found de novo mutations in 3,444 parent-child trios. They have identified 10 genes that confer substantial risk for schizophrenia, and 34 genes that are significant, and have made its results available in a browser (http://schema.broadinstitute.org). Two of the top 10 genes, GRIN2A and GRIA3, encode glutamate receptor subunits, supporting the hypothesis that diminished function of the glutamatergic system is involved in the pathogenesis of schizophrenia. They also found that both GRIN2A and SP4, which encodes a transcription factor, reside in loci that had already been implicated in schizophrenia by GWAS.

They compared these risk genes to genes implicated in other diseases, in particular neurodevelopmental delay, autism spectrum disorders, and intellectual disability, and found that there was significant overlap with autism. As such, it appears that the schizophrenia risk genes are more relevant to later-onset psychiatric disorders than to those with an early onset. While there is not complete overlap between the schizophrenia genes identified by exome sequencing and the genetic loci found by GWAS, some of the rare variants can be useful to fine-map GWAS loci and prioritize genes in them. The study was presented at the American Society of Human Genetics annual meeting held October 15-19, 2019, in Houston, TX, USA.

Related Links:
Broad Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.